Psychopharmacology

, Volume 225, Issue 1, pp 161–172 | Cite as

Driving on ice: impaired driving skills in current methamphetamine users

  • David Bosanquet
  • Hamish G. MacDougall
  • Stephen J. Rogers
  • Graham A. Starmer
  • Rebecca McKetin
  • Alexander Blaszczynski
  • Iain S. McGregor
Original Investigation

Abstract

Rationale

Previous research indicates a complex link between methamphetamine (METH) and driving performance. Acute dosing with amphetamines has improved driving-related performance in some laboratory studies, while epidemiological studies suggest an association between METH use, impaired driving, and accident culpability.

Methods

Current METH users were compared to a control group of nonusers on driving simulator performance. Groups were matched for age, gender, and driving experience. Subjects were assessed for current drug use, drug dependence, and drug levels in saliva/blood as well as personality variables, sleepiness, and driving performance.

Results

METH users, most of whom met the criteria for METH dependence, were significantly more likely to speed and to weave from side to side when driving. They also left less distance between their vehicle and oncoming vehicles when making a right-hand turn. This risky driving was not associated with current blood levels of METH or its principal metabolite, amphetamine, which varied widely within the METH group. Other drugs were detected (principally low levels of THC or MDMA) in some METH users, but at levels that were unlikely to impair driving performance. There were higher levels of impulsivity and antisocial personality disorder in the METH-using cohort.

Conclusions

These findings confirm indications from epidemiological studies of an association between METH use and impaired driving ability and provide a platform for future research to further explore the factors contributing to increased accident risk in this population.

Keywords

Methamphetamine Driving Risk Simulator Antisocial Impulsivity 

References

  1. Åkerstedt T, Gillberg M (1990) Subjective and objective sleepiness in the Active Individual. Int J Neurosci 52:29–37PubMedCrossRefGoogle Scholar
  2. Augsburger M, Donze N, Menetrey A, Brossard C, Sporkert F, Giroud C, Mangin P (2005) Concentration of drugs in blood of suspected impaired drivers. Forensic Sci Int 153:11–15PubMedCrossRefGoogle Scholar
  3. Barkley RA, Murphy KR, O'Connell T, Anderson D, Connor DF (2006) Effects of two doses of alcohol on simulator driving performance in adults with attention-deficit/hyperactivity disorder. Neuropsychology 20(1):77–87PubMedCrossRefGoogle Scholar
  4. Baskin-Sommers A, Sommers I (2006) The co-occurrence of substance use and high-risk behaviours. J Adolesc Health 38:609–611PubMedCrossRefGoogle Scholar
  5. Boorman SM, Papafotiou K (2007) The Victorian legislative framework for testing drivers for impairment caused by drugs other than alcohol: an evaluation of the characteristics of drivers tested from 2000 to 2005. Traffic Inj Prev 8:217–223PubMedCrossRefGoogle Scholar
  6. Cornish JL, Clemens, KJ, Thompson MR, Callaghan PD, Dawson B, McGregor IS (2008) High ambient temperature increases intravenous methamphetamine self-administration on fixed and progressive ratio schedules in rats. J Psychopharmacol (Oxf) 22:100–110CrossRefGoogle Scholar
  7. Couper FJ, Logan BK (2004) Drugs and human performance facts sheet. National Highway Traffic Safety Administration (NHTSA), US Department of Transportation Report Number: DOT HS 809 725Google Scholar
  8. Cox DJ, Merkel RL, Kovatchev B, Seward R (2000) Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial. J Nerv Ment Dis 188(4):230–234PubMedCrossRefGoogle Scholar
  9. Cruikshank CC, Dyer KR (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104:1085–1099CrossRefGoogle Scholar
  10. Degenhardt L, Topp L (2003) “Crystal meth” use among polydrug users in Sydney’s dance party subculture: characteristics, use patterns and associated harm. Int J Drug Policy 14:17–24CrossRefGoogle Scholar
  11. Degenhardt L, Dillon P, Duff C, Ross J (2006) Driving, drug use behaviour and risk perceptions of nightclub attendees in Victoria, Australia. Int J Drug Policy 17:41–46CrossRefGoogle Scholar
  12. Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn JRM, Robertson MD, Swann P (2003) The incidence of drugs in drivers killed in Australian road traffic crashes. Forensic Sci Int 134:154–162PubMedCrossRefGoogle Scholar
  13. Emonson DL, Vanderbeek RD (1995) The use of amphetamines in US Air-force tactical operations during desert shield and storm. Aviat Space Environ Med 66:260–263PubMedGoogle Scholar
  14. Fals-Stewart W, O'Farrell TJ, Freitas TT (2000) The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol 68:133–144Google Scholar
  15. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of the patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRefGoogle Scholar
  16. Gorlyn M, Keilp JG, Tryon WW, Mann JJ (2005) Performance test correlates of component factors of impulsiveness. Pers Individ Dif 38:1549–1559CrossRefGoogle Scholar
  17. Grotenhermen F, Leson G, Berghaus G, Drummer OH, Krüger HP, Longo M (2007) Developing limits for driving under cannabis. Addiction 102(12):1910–1917PubMedCrossRefGoogle Scholar
  18. Homer BD, Solomon TM, Moeller RW, Mascia A, DeRaleau L, Halkitis PN (2008) Methamphetamine abuse and impairment in social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull 134:565–567CrossRefGoogle Scholar
  19. Johnson BA, Ait-Daoud N, Wells LT (2000) Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on d-methamphetamine-induced cognitive and physiological changes in humans. Neuropsychopharmacology 22(5):504–512PubMedCrossRefGoogle Scholar
  20. Jones AW, Holmgren A (2005) Abnormally high concentrations of amphetamine in blood of impaired drivers. J Forensic Sci 50:1–6CrossRefGoogle Scholar
  21. Kaye S, Darke S, Duflou J, McKetin R (2008) Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction 103:1353–1360PubMedCrossRefGoogle Scholar
  22. Kelly TH, Foltin RW, Fischman MW (1991) The effects of repeated amphetamine exposure on multiple measures of human behavior. Pharmacol Biochem Behav 38:417–426PubMedCrossRefGoogle Scholar
  23. Kloeden CN, McLean AJ, Moore VM, Ponte J (1997) Travelling speed and the risk of crash involvement. Volume 1—findings. CR 172. Federal Office of Road Safety, CanberraGoogle Scholar
  24. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30:320–332PubMedCrossRefGoogle Scholar
  25. Krasnova IN, Cadet JL, Krasnova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60:379–407PubMedCrossRefGoogle Scholar
  26. Lapworth K, Dawe S, Davis P, Kavanagh D, Young R, Saunders J (2009) Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users. Addict Behav 34:380–385PubMedCrossRefGoogle Scholar
  27. Lecrubier Y, Sheehan DV, Weiller E (1997) The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12:224–231CrossRefGoogle Scholar
  28. Liguori A (2009) Simulator studies of drug induced driving impairment. In: Verster JC, Pandi-Perumal SR, Ramaekers JG, De Gier JJ (eds) Drugs, driving and traffic safety. Birkhauser, SwitzerlandGoogle Scholar
  29. Logan BK, Schwilke EW (1996) Drug and alcohol use in fatally injured drivers in Washington State. J Forensic Sci 41(3):505–510PubMedGoogle Scholar
  30. Logan BK, Fligner CL, Haddix T (1998) Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci 43(1):28–34PubMedGoogle Scholar
  31. Louwerens JW, Gloerich ABM, de Vries G, Brookhuis K, O'Hanlon JF (1987) The relationship between driver's blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: Noordzij PC, Roszbach R (eds) Alcohol, drugs and traffic safety: proceedings of the 10th International Conference on Alcohol, Drugs and Traffic Safety. Excerpta Medica, Amsterdam, pp 183–192Google Scholar
  32. Mancino MJ, Gentry BW, Feldman Z, Mendelson J, Oliveto A (2011) Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse 37:131–136PubMedCrossRefGoogle Scholar
  33. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136–145PubMedGoogle Scholar
  34. Maxwell JC (2005) Emerging research on methamphetamine. Curr Opin Psychiatr 18:235–242CrossRefGoogle Scholar
  35. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM (2005) The nature, time course and severity of methamphetamine withdrawal. Addiction 100(9):1320–1329PubMedCrossRefGoogle Scholar
  36. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ (2005) Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 13(3):141–154PubMedCrossRefGoogle Scholar
  37. Mitler MM, Hajdukovic R, Erman MK (1993) Treatment of narcolepsy with methamphetamine. Sleep 16(4):306–317PubMedGoogle Scholar
  38. O'Hanlon JF (1984) Driving performance under the influence of drugs: rationale for, and application of a new test. Br J Clin Pharmacol 18:S121–S132CrossRefGoogle Scholar
  39. Paaver M, Eensoo D, Pulver A, Harro J (2006) Adaptive and maladaptive impulsivity, platelet monoamine oxidase (MAO) activity and risk-admitting in different types of risky drivers. Psychopharmacology (Berl) 186:32–40CrossRefGoogle Scholar
  40. Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol 51:568–774CrossRefGoogle Scholar
  41. Pennay AE, Lee NK (2010) Putting the call out for more research: the poor evidence base for treating methamphetamine withdrawal. Drug Alcohol Rev 30:216–222CrossRefGoogle Scholar
  42. Ramaekers JG, Kuypers KPC, Samyn N (2006) Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal. Addiction 101(11):1614–1621PubMedCrossRefGoogle Scholar
  43. Ramaekers JG, Berghaus G, van Laar MW, Drummer OH (2009) Dose related risk of motor vehicle crashes after cannabis use: an update. In: Verster JC, Pandi-Perumal SR, Ramaekers JG, de Gier JJ (eds) Drugs, driving and traffic safety. Birkhauser, SwitzerlandGoogle Scholar
  44. Rapoport JL, Banina MC (2007) Impact of psychotropic medications on simulated driving—a critical review. CNS Drugs 21:503–519PubMedCrossRefGoogle Scholar
  45. Richards JB, Sabool KE, de Wit H (1999) Effects of methamphetamine on the adjusting amount procedure, a model of impulsive behavior in rats. Psychopharmacology (Berl) 146:432–439CrossRefGoogle Scholar
  46. Ryb GE, Dischinger PC, Kufera JA, Read KM (2006) Risk perception and impulsivity: association with risky behaviors and substance abuse disorders. Accid Anal Prev 38:567–573PubMedCrossRefGoogle Scholar
  47. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, Iwata Y, Tsuchiya KJ, Suda S, Suzuki K, Kawai M, Takebayashi K, Yamamoto S, Matsuzaki H, Ueki T, Mori N, Gold MS, Cadet JL (2008) Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28:5756–5761PubMedCrossRefGoogle Scholar
  48. Shappell SA, Kearns GL, Valentine JL, Neri DF, DeJohn CA (1996) Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man. J Clin Pharmacol 36:1051–1063PubMedCrossRefGoogle Scholar
  49. Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J, Brady D, McKetin R, Mattick RP, Wodak A (2009) A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 104:224–233PubMedCrossRefGoogle Scholar
  50. Sheehan DV, Lecrubier Y, Harnett-Sheehan K (1998) The Mini International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychol 59(Suppl 20):22–33Google Scholar
  51. Silber BY, Croft RJ, Papafotiou K, Stough CK (2006) The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology (Berl) 187:154–169CrossRefGoogle Scholar
  52. Silber BY, Croft RJ, Downey LA, Camfield DA, Papafotiou K, Swann P, Stough C (2012) The effect of d,l-methamphetamine on simulated driving performance. Psychopharmacology (Berl) 219:1081–1087CrossRefGoogle Scholar
  53. Stough C, Downey LA, King R, Papafotiou K, Swann PEO (2012) The acute effects of 3,4-methylenedioxymethamphetamine and methamphetamine on driving: a simulator study. Accid Anal Prev 45:493–497PubMedCrossRefGoogle Scholar
  54. Suzanne GD, Fatovich DM, McCoubrie DL, Daly FF (2007) Amphetamine-related presentations to an inner-city tertiary emergency department: a prospective evaluation. Med J Aust 186:336–339Google Scholar
  55. Tombaugh TN, McIntyre NJ (1992) The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc 40:922–935PubMedGoogle Scholar
  56. Vassallo S, Smart D, Sanson A, Cockfield S, Harris A, McIntyre A, Harrison W (2008) Risky driving among young Australian drivers II: co-occurrence with other problem behaviours. Accid Anal Prev 40:376–386PubMedCrossRefGoogle Scholar
  57. Vermeeren A, Leufkens T, Verster JC (2009) Effects of anxiolytics on driving. In: Verster JC, Pandi-Perumal SR, Ramaekers JG, de Gier JJ (eds) Drugs, driving and traffic safety. Birkhauser, SwitzerlandGoogle Scholar
  58. Verster JC, Roth T (2011) Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med 4:359–371PubMedGoogle Scholar
  59. Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH, Dolan RJ, Hallett M (2010) Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 65:135–142PubMedCrossRefGoogle Scholar
  60. Walburga M, Laar V, Volkerts ER, Van Paul WAP (1992) Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 12:86–95CrossRefGoogle Scholar
  61. Winek CL, Wahba WW, Winek CL Jr, Balzer TW (2001) Drug and chemical blood-level data 2001. Forensic Sci Int 122(2–3):107–123PubMedCrossRefGoogle Scholar
  62. Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, Rawson R, London ED (2010) Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 105:1809–1818PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • David Bosanquet
    • 1
  • Hamish G. MacDougall
    • 1
  • Stephen J. Rogers
    • 1
  • Graham A. Starmer
    • 2
  • Rebecca McKetin
    • 3
  • Alexander Blaszczynski
    • 1
  • Iain S. McGregor
    • 1
  1. 1.School of PsychologyUniversity of SydneySydneyAustralia
  2. 2.Department of PharmacologyUniversity of SydneySydneyAustralia
  3. 3.Centre for Research on AgeingHealth and Wellbeing The Australian National UniversityCanberraAustralia

Personalised recommendations